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This study aimed to provide a long-term cost comparison of patients using additional
homeopathic treatment (homeopathy group) with patients using usual care (control group)
over an observation period of 33 months.
Methods
Health claims data from a large statutory health insurance company were analysed from
both the societal perspective (primary outcome) and from the statutory health insurance per-
spective (secondary outcome). To compare costs between patient groups, homeopathy and
control patients were matched in a 1:1 ratio using propensity scores. Predictor variables for
the propensity scores included health care costs and both medical and demographic vari-
ables. Health care costs were analysed using an analysis of covariance, adjusted for base-
line costs, between groups both across diagnoses and for specific diagnoses over a period
of 33 months. Specific diagnoses included depression, migraine, allergic rhinitis, asthma,
atopic dermatitis, and headache.
Results
Data from 21,939 patients in the homeopathy group (67.4% females) and 21,861 patients in
the control group (67.2% females) were analysed. Health care costs over the 33 months
were 12,414 EUR [95% CI 12,022–12,805] in the homeopathy group and 10,428 EUR [95%
CI 10,036–10,820] in the control group (p<0.0001). The largest cost differences were attrib-
uted to productivity losses (homeopathy: EUR 6,289 [6,118–6,460]; control: EUR 5,498
[5,326–5,670], p<0.0001) and outpatient costs (homeopathy: EUR 1,794 [1,770–1,818];
control: EUR 1,438 [1,414–1,462], p<0.0001). Although the costs of the two groups con-
verged over time, cost differences remained over the full 33 months. For all diagnoses,
homeopathy patients generated higher costs than control patients.
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Conclusion
The analysis showed that even when following-up over 33 months, there were still cost dif-
ferences between groups, with higher costs in the homeopathy group.
Introduction
To date, the majority of German statutory health insurance companies reimburse homeopathy
within the context of integrated care contracts [1]. Homeopathy consists of an extensive con-
sultation and the prescription of homeopathic medicines. These homeopathic medicines are
often diluted up to a concentration to which no molecule of the original substance can be
found [2] and there is no valid scientific explanation for the mechanism of action of these
diluted homeopathic medicines [2,3]. Because of this, critical voices are rising arguing that
spending money on homeopathic treatments is a waste of money in times of limited resources
for health care [4,5]. Furthermore, they see the reimbursement of homeopathic treatments
statutory health insurance companies as an indirect legitimation of a non-scientific concept
[5,6]. Yet, supporters of homeopathic treatment argue that individually prescribed homeo-
pathic medicines are superior to placebo and quote respective meta-analyses [7], while critics
quote those meta-analyses that come to the opposite conclusions [8].
Others explain the benefits by the fact that a homeopathic treatment consists of both the
prescription of homeopathic medicines and a time-extensive consultation which allows to care
more intensively for patients’ needs [9,10]. That homeopathic physicians take more time to
treat their patients might at least partly explain the huge interest of patients in homeopathy
and their demand for homeopathic treatments [11,12].
The integrated care contract ‘homeopathy’, this analysis is based on, is optional for both
patients and physicians. Patients can subscribe to the integrated care contract at any time.
Patients in the integrated care contract ‘homeopathy’ can receive homeopathic treatment in
addition to usual care. Under the integrated care contract, the cost of the homeopathic treat-
ment is covered by the patient’s insurance company; the patient receives the homeopathic
treatment for free and the physician receives additional reimbursement. The evidence from
economic evaluations of homeopathy is inconclusive: whereas some studies have shown that it
offers cost-saving potential [13–15], other evaluations have shown it to be either more expen-
sive [16–18] or to have similar costs [19] as usual care. A recent review by Viksveen concluded
that the methodologies used in current studies are often weak and that it is therefore impossi-
ble to derive unequivocal conclusions from cost evaluations of homeopathy [20]. Our previous
analyses of the integrated care contract ‘homeopathy’ showed that the cumulative costs of
patients using homeopathic treatment in addition to usual care over an 18-month period were
higher than the costs of patients using only usual care. However, the costs incurred by the two
groups seemed to converge towards the end of the observation period [21] This finding
emphasized the need for further analyses based on a longer observation period.
Therefore, the aim of the current study was to compare the health care costs of patients
using homeopathic treatment in addition to usual care with the costs of patients using only
usual care over a period of 33 months.
Methods
Study design and participants
We included male and female insureds with no age constraints. Patients were labelled as
homeopathy patients if they subscribed to the integrated care contract homeopathy in 2011,
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regardless of whether they used homeopathy during the study. Subscription to the integrated
care contract implied that the homeopathy patients had visited a physician in the first three
months of the observational period. To level out a possible discrepancy in health care resource
consumption between homeopathy patients and controls, control patients had to have visited
a physician during the first three months of the study period. Moreover, control patients had
to meet the following additional inclusion criteria: they did not subscribe to the integrated care
contract homeopathy during the study, they were continuously insured by the health insur-
ance company, and they were successfully matched with a homeopathy patient using propen-
sity scores. For more details on the selection of patients, see Ostermann et al. [21]. In the long-
term analysis discussed here, we followed up with patients from the previous analysis. How-
ever, patients who left the statutory health insurance company prior to 18 months (i.e., before
the end of the previous study) were excluded from the analyses. In addition to analysing the
health care costs of all patients, independently from a specific diagnosis, we also subdivided
patients into the following physician-confirmed diagnosis-groups: depression (ICD-10 F32),
migraine (G43), allergic rhinitis (J30), allergic asthma (J45), atopic dermatitis (L20), and ten-
sion headache (R51). Cost analysis of these subgroups was not limited to the specific costs
associated with the disease.
We followed the guidelines for secondary data analyses. De-identified health claims data
were provided by the statutory health insurance company. We had no key for de-identifying
the data. This study was approved by the Ethics Committee of the Charite´ - Universita¨tsmedi-
zin Berlin (EA2/121/12).
Propensity score matching
Because subscription to the integrated care contract homeopathy was open to all insureds of
the statutory health insurance company, we conducted an observational analysis. To balance
baseline characteristics and minimize selection bias of patients between groups, homeopathy
and control patients were matched 1:1 using propensity scores [22]. For patients in both
groups, propensity scores for the outcome ‘user of the integrated care contract’ (yes/no) were
calculated. Propensity scores were computed using the following covariates: sex (male/female),
age (continuous), comorbidities (disease present, yes/no), cumulative different unit costs one
year prior to the study period (continuous), length of stay in a hospital (continuous), days of
sick leave (continuous) and statutory sick pay costs (continuous), duration of outpatient reha-
bilitation (continuous), level of care intensity (‘1’, ‘2’, ‘3’ or ‘3 plus’), disease-management-
program participation (yes/no), usage of GP-centred care (yes/no) and population density
(inhabitants per square kilometre, continuous). A caliper width of 0.25 of the standard devia-
tion of the logit of the propensity score was applied to match control patients to homeopathy
patients. As seasonal effects could bias patients’ characteristics and costs, the matching process
was performed separately for each quarter of the year 2011. For homeopathy patients, the
index date of the observational period was their subscription date to the integrated care con-
tract. Cumulative costs one year prior to the study period were therefore calculated from the
index date over a period of 12 months. For the control patients, the index date of the matched
homeopathy patients, which was required for the calculation of the propensity score, was
known only after the matching process was completed. To overcome this obstacle, the index
date for the controls was specified as the middle of the quarter of the respective matching pro-
cess. For each of the four matching groups, health claims data were analysed for a total of 45
months, including 12 months before and 33 months after the respective index date. Data were
therefore analysed from January 2010 to September 2014.
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Economic analysis
Health care costs were analysed from the societal perspective across diagnoses (primary analy-
sis) and between diagnoses (secondary analysis). Additionally, costs were analysed from the
perspective of the statutory health insurance company. To factor in the productivity loss from
the societal perspective, we adopted the human capital approach with a daily mean gross
income of EUR 239.20 and a cut-off period of six weeks [23]. A cut-off period of six weeks was
used because, in Germany, the employer continues to pay the employee’s salary in case of ill-
ness up to six weeks. Statutory sick pay from the statutory health insurance is paid only after
six weeks. Costs were not discounted. Negative costs in the dataset that could have arisen due
to accounting reasons from previous reimbursement periods were set at zero to avoid interpre-
tation issues. To monitor the source of costs for outpatient care, outpatient costs were divided
into costs generated by homeopathic physicians who participated in the integrated care con-
tract homeopathy and other physicians. Controls could consult homeopathic physicians; how-
ever, they could only do so outside the framework of the integrated care contract.
Statistical analysis
For the primary endpoint, cumulative health care costs were analysed from a societal perspec-
tive across diagnoses and between groups after 33 months. We performed an analysis of co-
variance (ANCOVA), controlling for each group’s respective baseline costs (cumulative costs
from month -12 until month 0). Total costs consisted of outpatient care costs (generated by
homeopathic physicians and by other physicians), medication costs, productivity losses, costs
of the integrated care contract, inpatient costs and other costs. Total costs and single cost types
were added for the period of 12 months before the start of the observational period (month -12
to month 0) and for the subsequent 33 months. Costs incurred after the start of the observa-
tional period were divided into three-month intervals (months 1–3, 4–6, 7–9, 10–12, 13–15,
16–18, 19–21, 22–24, 25–27, 28–30, 31–33). Costs were compared between groups and be-
tween diagnoses using ANCOVAs, with the respective baseline cost values as the covariates.
To assess how the cumulative total costs developed over time, cost progression over the obser-
vation period was analysed between groups and across diagnoses, from both the societal and
statutory health insurance perspectives. The test for the primary end point was two-sided with
a significance level of 0.05. All other tests were exploratory and were two-sided with a signifi-
cance level of 0.05. SAS software version 9.3 (SAS Institute Inc., Cary, U.S.) was used for partic-
ipant matching. The analyses were computed following a pre-specified statistical analysis plan
and using R version 3.1.0 [24].
Results
Out of all 22,275 patients per group from the previous study, 336 patients (1.5%) from the
homeopathy group and 414 patients (1.9%) from the control group left the statutory health
insurance company. Therefore, 21,939 patients (67.4% female) in the homeopathy group and
21,861 patients (67.2% female) in the control group could be analysed. The sample was quite
comparable in terms of baseline characteristics (Table 1).
Costs from month -12 to month 0 were comparable between homeopathy patients and con-
trols (societal perspective: homeopathy EUR 3666 [3549–3783]; controls EUR 3769 [3654–
3884]; statutory health insurance perspective: homeopathy EUR 1841 [1770–1912]; controls
EUR 1846 [1777–1914]).
The adjusted mean costs after 33 months were EUR 12,414 [95% CI 12,022–12,805] in the
homeopathy group and EUR 10,429 [10,037–10,821] in the control group (mean difference
EUR 1985 [1946–2024], p<0.0001). Productivity loss (homeopathy EUR 6,289 [6,118–6,460];
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controls EUR 5,498 [5,326–5,670]; mean difference: EUR 791 [765–817], p<0.0001) and out-
patient care (homeopathy EUR 1,794 [1,770–1,818]; controls EUR 1,438 [1,414–1,462]; mean
difference: EUR 356 [346–366], p<0.0001) accounted for the majority of total costs (Table 2).
Subtracting productivity loss from total costs revealed a cost difference of EUR 1,130 [803–
1,457] (homeopathy EUR 6,093 [5,766–6,420]; controls EUR 4,963 [4,635–5,290]). In both
groups, outpatient care costs were predominantly generated by other physicians (homeopathy
EUR 1,531 [1,501–1,561]; controls EUR 1,355 [1,325–1,384], p<0.0001). Apart from treating
homeopathy patients, physicians who participated in the integrated care contract (‘homeo-
pathic physician’) could treat control patients outside the framework of the integrated care
contract with either homeopathy or conventional medicine. Homeopathic physicians only
generated approximately 13% of outpatient care costs in the homeopathic group (EUR 230
[227–233]) and 3% of outpatient care costs in the control group (EUR 39 [36–42], p<0.0001).
Table 1. Baseline characteristics of all patients. Data include the mean (SD) and the number of persons (%).
Homeopathy (n = 21939) Control (n = 21861)
Women (n) 14779 (67.4) 14969 (67.2)
Age (years) 33.86 (20.0) 34.2 (20.1)
Sick leave days previous 12 months 9.61 (35.38) 10.19 (36.45)
Hospital cases previous 12 months 0.22 (0.69) 0.21 (0.64)
Cumulated costs previous 12 months
Total 1841 (5355) 1846 (5140)
Medication 300 (2882) 314 (2444)
Inpatient 552 (3059) 552 (3147)
Diagnosis (n)
Other 13261 (60.4) 13228 (60.5)
Depressive disorder (F33) 3033 (13.8) 3018 (13.8)
Migraine (G43) 880 (4.0) 872 (4.0)
Allergic rhinitis (J30) 1128 (5.1) 1119 (5.1)
Asthma (J45) 1229 (5.6) 1222 (5.6)
Atopic dermatitis (L20) 1456 (6.6) 1460 (6.7)
Headache (R51) 952 (4.3) 942 (4.3)
State of residence (n)
Abroad 35 (0.2) 24 (0.1)
Baden-Wuerttemberg 3203 (14.6) 2234 (10.2)
Bavaria 2881 (13.1) 2388 (10.9)
Berlin 2222 (10.1) 1934 (8.9)
Brandenburg 427 (2.0) 534 (2.4)
Bremen 275 (1.3) 171 (0.8)
Hamburg 1253 (5.7) 1014 (4.6)
Hesse 1844 (8.4) 1995 (9.1)
Mecklenburg-Western Pomerania 232 (1.1) 380 (1.7)
Lower Saxony 2094 (9.5) 2281 (10.4)
North-Rhine Westphalia 4097 (18.7) 5719 (26.2)
Rhineland-Palatinate 870 (4.0) 954 (4.4)
Saarland 196 (0.9) 203 (0.9)
Saxony 406 (1.9) 432 (2.0)
Saxony-Anhalt 131 (0.6) 299 (1.4)
Schleswig-Holstein 1486 (6.8) 1021 (4.7)
Thuringia 287 (1.3) 278 (1.3)
https://doi.org/10.1371/journal.pone.0182897.t001
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Across all diagnoses, costs for homeopathy patients were higher than costs for control
patients over the period of 33 months. The range of costs varied greatly across diagnoses, with
the highest costs being generated by patients with depression (homeopathy (n = 3,033), EUR
25,107 [95% CI 24,131–26,083]; controls (n = 3,018), EUR 21,892 [20,913–22,870], p<0.0001),
and the lowest costs generated by patients with atopic dermatitis (homeopathy (n = 1,456)
EUR 7,425 [6,894–7,955]; controls (n = 1,460), EUR 6,123 [5,593–6,653], p = 0.001). However,
this difference among groups was not always statistically significant (Table 3).
The number of homeopathy patients who generated costs under the integrated care con-
tract during months 1–3 was 100% (n = 21,928). During months 4–6 the number of patients
generating costs dropped to 56% (n = 12,331). At the end of our previous study, in months 16–
18, only 26% (n = 5,782) of the homeopathy patients still generated costs under the integrated
care contract. Five months later, during months 31–33 (the end of our current study), this
number continued to drop to 20% (n = 4,326).
Total costs from the societal perspective were two times higher than total costs from the
statutory health insurance perspective (homeopathy EUR 6,507 [6,173–6,841]; controls EUR
5,199 [4,865–5,534], p<0.0001), with similar cost progression in both groups. Higher costs
from the societal perspective were mainly driven by indirect costs, i.e., productivity loss. The
costs from the statutory health insurance perspective, due to patients’ inability to work and
statutory sick pay, accounted for approximately 10% of productivity loss. The greatest cost dif-
ference was observed in months 1 to 3, which coincides with the beginning of the integrated
care contract and with adjusted mean costs of EUR 115 [115–115] (from both perspectives) in
the homeopathic group. After month three the cost difference between the groups decreased.
However, a cost difference between the groups persisted beyond month 18 –the end of the pre-
vious study–and continued until the end of this study’s observation time, i.e., month 33 (Fig
1). The cost difference between the groups from month 18 until month 33 remained relatively
steady. The cost progressions within the specific diagnoses were generally similar to the cost
progressions across diagnoses. Greater variations in the data were due to smaller numbers of
subjects. The cost progression of patients with headache (n = 1894) is an exception. A deeper
analysis of headache patients revealed that a cost difference persisted only from months 1 to
12. After month twelve, no difference in costs between the groups could be observed (Fig 2).
Discussion
Key results
A comparison of adjusted health care costs showed that the total costs and unit costs of
patients using homeopathy after 33 months of observation under the integrated care contract
Table 2. Adjusted means for different cost types over 33 months after the start of the integrated care contract for all patients, societal perspective.
Homeopathy (n = 21939) Control (n = 21861)
Type of cost N Cost utilization Adj. mean (EUR) (95% CI) N Cost utilization Adj. mean (EUR) (95% CI) p-value
Integrated care contract 21,938 299 (297–302) - - <0.0001
Outpatient 21,939 1,794 (1,770–1,818) 21,861 1,438 (1,414–1,462) <0.0001
Homeopathic physician 21,386 230 (227–233) 948 39 (36–42) <0.0001
Other physician 21,751 1,531 (1,501–1,561) 21,861 1,355 (1,325–1,384) <0.0001
Medication 20,614 1,461 (1,209–1,713) 20,907 1,069 (816–1,321) 0.031
Productivity loss 9,450 6,289 (6,118–6,460) 9,528 5,498 (5,326–5,670) <0.0001
Inpatient 6,831 1,674 (1,593–1,755) 6,527 1,485 (1,404–1,567) 0.001
Other 28,266 106 (103–109) 24,291 102 (99–105) 0.031
Total 21,939 12,414 (12,022–12,805) 21,861 10,429 (10,037–10,821) <0.0001
https://doi.org/10.1371/journal.pone.0182897.t002
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Table 3. Adjusted means for different cost types and diagnoses over 33 months after the beginning of the integrated care contract, societal
perspective.
Homeopathy Control
Type of cost N Cost utilization Adj. mean (EUR) (95% CI) N Cost utilization Adj. mean (EUR) (95% CI) p-value
Depression
n = 6051
Integrated care contract 3,033 364 (357–371) - - <0.0001
Outpatient 3,033 3,228 (3,150–3,306) 3,018 2,607 (2,529–2,686) <0.0001
Homeopathic physician 2,944 297 (286–308) 153 63 (51–74) <0.0001
Other physicians 3,026 2,780 (2,706–2,854) 3,018 2,455 (2,380–2,529) <0.0001
Medication 2,937 2,099 (1,846–2,353) 2,970 1,965 (1,711–2,219) 0.464
Productivity loss 1,891 14,741 (13,994–15,489) 1,786 12,808 (12,058–13,557) <0.0001
Inpatient 1,387 3,070 (2,822–3,317) 1,262 2,738 (2,489–2,986) 0.064
Other 5,392 195 (182–207) 4,686 191 (178–203) 0.635
Total 3,033 25,107 (24,131–26,083) 3,018 21,892 (20,913–22,870) <0.0001
Migraine
n = 1752
Integrated care contract 880 329 (318–341) - - <0.0001
Outpatient 880 1,981 (1,881–2,081) 872 1,653 (1,553–1,753) <0.0001
Homeopathic physician 849 239 (228–251) 33 38 (26–49) <0.0001
Other physicians 878 1,652 (1,557–1,747) 872 1,549 (1,453–1,644) 0.132
Medication 842 944 (772–1,116) 851 992 (820–1,165) 0.695
Productivity loss 549 8,337 (7,401–9,273) 546 7,560 (6,619–8,500) 0.251
Inpatient 312 2,321 (1,616–3,026) 294 1,803 (1,094–2,511) 0.310
Other 1,315 95 (85–106) 1,125 85 (75–96) 0.190
Total 880 14,721 (13,316–16,126) 872 12,797 (11,385–14,208) 0.058
All. Rhinitis
n = 2247
Integrated care contract 1,128 325 (315–335) - - <0.0001
Outpatient 1,128 1,646 (1,570–1,722) 1,119 1,307 (1,231–1,383) <0.0001
Homeopathic physician 1,096 234 (223–244) 50 29 (19–39) <0.0001
Other physicians 1,122 1,349 (1,277–1,422) 1,119 1,222 (1,150–1,295) 0.015
Medication 1,069 1,066 (829–1,303) 1,090 786 (548–1,024) 0.103
Productivity loss 537 5,427 (4,796–6,058) 539 4,652 (4019–5,286) 0.090
Inpatient 302 1,097 (929–1,264) 320 934 (766–1,102) 0.177
Other 1,441 78 (68–88) 1,233 73 (63–82) 0.475
Total 1,128 10,222 (9,390–11,055) 1,119 8,352 (7,516–9,188) 0.002
Asthma
n = 2451
Integrated care contract 1,229 319 (308–329) - - <0.0001
Outpatient 1,229 1,920 (1,789–2,051) 1,222 1,579 (1,448–1,711) <0.0001
Homeopathic physician 1,195 241 (230–253) 46 51 (40–62) <0.0001
Other physicians 1,224 1,635 (1,427–1,843) 1,222 1,528 (1,319–1,736) 0.476
Medication 1,206 1,488 (1,260–1,716) 1,209 1,271 (1,043–1,500) 0.187
Productivity loss 526 5,808 (5,190–6,426) 515 4,605 (3,986–5,225) 0.007
Inpatient 421 1,719 (1,402–2,036) 381 1,696 (1,378–2,014) 0.920
Other 1,692 107 (94–121) 1,432 110 (96–123) 0.807
Total 1,229 12,178 (11,238–13,118) 1,222 10,145 (9,202–11,088) 0.003
Atopic dermatitis
n = 2916
Integrated care contract 1,456 282 (274–290) - - <0.0001
Outpatient 1,456 1,533 (1,439–1,626) 1,460 1,186 (1,092–1,279) <0.0001
Homeopathic physician 1,429 206 (199–213) 68 38 (31–45) <0.0001
Other physicians 1,452 1,312 (1,165–1,459) 1,460 1,095 (949–1,242) 0.041
Medication 1,416 806 (684–929) 1,436 734 (612–856) 0.411
Productivity loss 455 3,201 (2,830–3,572) 423 2,555 (2,184–2,926) 0.016
Inpatient 398 897 (752–1,042) 383 868 (723–1,013) 0.784
Other 1,662 87 (79–94) 1,451 84 (76–91) 0.579
Total 1,456 7,425 (6,894–7,955) 1,460 6,123 (5,593–6,653) 0.001
(Continued)
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were higher than the costs for patients not using homeopathy. Cost differences between these
two groups persisted throughout the observation period, from month 0 until month 33. Cost
differences between groups decreased from month 0 until month 18. From month 18 until
month 33, the cost progression of both groups ran almost parallel, although at different levels.
Strengths and limitations
A strength of the current analysis is the large sample size. Using health claims data from a large
statutory health insurance company allowed us to analyse 43,800 insureds over a period of
Table 3. (Continued)
Homeopathy Control
Type of cost N Cost utilization Adj. mean (EUR) (95% CI) N Cost utilization Adj. mean (EUR) (95% CI) p-value
Headache
n = 1894
Integrated care contract 952 289 (279–300) - - <0.0001
Outpatient 952 1,964 (1,857–2,070) 942 1,484 (1,377–1,591) <0.0001
Homeopathic physician 926 207 (197–217) 39 41 (31–51) <0.0001
Other physicians 950 1,669 (1,567–1,770) 942 1,374 (1,272–1,475) <0.0001
Medication 911 952 (736–1,168) 922 976 (759–1,192) 0.879
Productivity loss 444 7,219 (6,336–8,102) 440 6,183 (5,295–7,071) 0.105
Inpatient 332 1,604 (1,225–1,984) 328 1,734 (1,353–2,115) 0.637
Other 1,388 95 (86–104) 1172 92 (83–101) 0.668
Total 952 12,733 (11,528–13,937) 942 11,328 (10,118–12,539) 0.107
https://doi.org/10.1371/journal.pone.0182897.t003
Fig 1. Mean overall cost (EUR) progression by group from the societal and statutory health insurance perspectives from month -12 until month 33.
Error bars denote 95% CIs. Months 1 to 3 indicate the start of the integrated care model. Costs from month 1 onward are adjusted to baseline costs (month
-12 to month 0).
https://doi.org/10.1371/journal.pone.0182897.g001
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nearly four years. Additionally, our main result, that the costs of homeopathy patients were
higher than the costs of controls, remains constant across all sub-diagnoses and between the
statutory health insurance and societal perspectives. This strengthens our confidence in our
results. Moreover, the data were not restricted to a specific geographic area because the statu-
tory health insurance company has clients throughout Germany. However, using data from
only one statutory health insurance company limits the generalizability of the results. Clients
of this statutory health insurance tend to be higher earners and better educated than clients
using other German statutory health insurance companies. Using the propensity-score match-
ing approach, we were able to generate good comparability between the groups but only in
terms of the specific variables that influenced the propensity score. A limitation of this study is
that it only analysed costs. Therefore, it is not possible to make conclusions about the out-
comes of the integrated care contract. As every client of the statutory health insurance could
potentially participate in the integrated care contract, a prospective randomized controlled
study design was not possible. Therefore, an observational study design was used instead,
which could have resulted in selection bias regarding the patients. Using the propensity score
approach, we could only control for variables that were available in the health claims data. As
we did not have information about such variables as social status or health consciousness, we
cannot rule out the possibility that the groups were dissimilar in these characteristics. The
homeopathic physicians who took part in the integrated care contract were both convention-
ally and homoeopathically trained and could provide both types of treatment within the health
insurance system. The health claims data did not include any information about the type of
treatment that generated common outpatient costs. Therefore, we were unaware which type of
treatment, homeopathy or conventional medicine, the homeopathic physician offered to
homeopathy patients or controls, apart from the specifications of the integrated care contract.
Interpretation
Long-term analyses of studies are important because many studies have only a short-term
observational period despite the fact that some consequences of health interventions might
only be detectable long-term. In an observational study examining the effects and costs of
homeopathic treatment in children with atopic eczema, homeopathic treatment was not supe-
rior to conventional treatment, but it was associated with higher costs after 12 months [17]. A
follow-up analysis of the patients over 36 months showed that outcomes for homeopathy
patients were not superior to outcomes for conventionally treated patients and that costs for
homeopathy patients were still twice as high as costs for conventionally treated patients [18].
Our previously published short-term economic evaluation of the homeopathy integrated care
contract showed that adjusted total costs were higher in the homeopathy group compared to
the usual care group [21]. However, this cost difference seemed to decrease by month 18, the
end of the observational study period [21]. To better understand these developments over
time, we decided to lengthen the observation period. This longer study showed that even after
33 months a relevant cost difference persisted.
Health claims data make it possible to perform long-term analyses with relative ease, as the
data are already collected for administrative purposes. Compared to collecting and analysing
primary data, re-analysing secondary data is economical in terms of both time and money. We
Fig 2. Mean overall cost (EUR) progression by group and diagnosis from the societal (solid line) and statutory
health insurance (dashed line) perspectives from month -12 until month 33. Error bars denote 95% CIs. Months 1 to
3 indicate the start of the integrated care model. Costs from month 1 onward are adjusted to baseline costs (month -12 to
month 0).
https://doi.org/10.1371/journal.pone.0182897.g002
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do not have data on the number of patients in the homeopathy group who remained sub-
scribed to the integrated care contract for 33 months. However, the data do reveal the number
of patients who generated costs during each three-month interval under the integrated care
contract. The number of patients in the homeopathy group who generated costs under the
integrated care contract decreased rapidly from the start of the observation period until
months 4–6 and continued to drop until the end of the observation period, at which point
only a fifth of the homeopathy patients were still generating costs under the integrated care
contract. The total costs generated at the end of our previous study might therefore not be
attributable entirely to the integrated care contract. The long-term cost difference might be
attributable to the higher health consciousness of patients who voluntarily subscribe to an inte-
grated care contract compared to control patients. As discussed previously, a visit to a homeo-
pathic physician, especially the initial contact between physician and patient, could generate
an extensive period of physician-patient communication. This might initiate further treat-
ments and consultations with additional physicians [21]. In our short-term observation period,
a comparable number of patients in each group had a mental diagnosis at baseline. However,
at month 1–3, 8,660 (38.9%) more mental illnesses had been diagnosed in the homeopathy
group compared to the control group. As mental illnesses are chronic conditions, treatment
should continue over a long period of time. Therefore, contact with health services–and associ-
ated costs–could increase among these patients [25–27]. This might partially explain the cost
difference between the groups over 33 months.
Conclusion
These long-term cost analyses have produced similar results to previous short-term analyses.
After nearly three years, the costs of patients who received homeopathy in addition to usual
care were still higher than the costs of patients receiving only standard care.
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